What Has Been The Historical And Current Growth Of The Antibody Contract Manufacturing Market?
The antibody contract manufacturing market has seen considerable growth due to a variety of factors.
•In the past few years, the antibody contract manufacturing market has witnessed rapid expansion. The size of this market is anticipated to increase from $14.8 billion in 2024 to $16.84 billion in 2025, with a compound annual growth rate (CAGR) of 13.8%.
The remarkable growth in the previous era can be ascribed to a surge in the demand for monoclonal antibodies, a shift in preference towards personalized medicine, cost efficiency, strict regulatory norms, and the internationalization of biologics.
What Is The Forecast For The Antibody Contract Manufacturing Market By 2029?
The antibody contract manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the antibody contract manufacturing market is projected to experience fast-paced expansion. The market value is anticipated to reach a staggering $29.86 billion in 2029, with an impressive compound annual growth rate (CAGR) of 15.4%.
This growth during the forecast period is due to factors such as heightened r&d spending, the expansion of bispecific and multispecific antibodies, the advent of antibody-drug conjugates (ADCs), improved healthcare facilities, and increased government initiatives. Some key trends predicted for this period include digitization and data analytics, innovative upstream technologies, modern downstream processing methods, sustainability initiatives and integration of contract development and manufacturing or CDMO.
Which Drivers Are Accelerating Growth In The Antibody Contract Manufacturing Market?
The growth of the antibody contract manufacturing market is predicted to accelerate due to the increasing number of clinical trials. These trials involve human participants and aim to assess the safety and efficacy of new medical treatments, procedures, or diagnostics. The growing number of trials related to antibody-based therapies or diagnostics necessitates the procurement of high-quality antibodies to ensure a reliable and compliant supply for these trials. For instance, data from ClinicalTrials.gov, a division of the National Institutes of Health (NIH), a US government agency in charge of medical research, indicates that the number of registered clinical trials increased from 399,499 in 2022 to 437,533 in May 2023 across all 50 US states and 221 countries. Notably, about 241,498 studies, or 53% of the total, were registered outside the United States, while the remaining 140,492 studies (31%) were registered within the United States. Consequently, this surge in clinical trials is fueling the expansion of the antibody contract manufacturing market.
What Are The Core Segments Of The Global Antibody Contract Manufacturing Market?
The antibody contract manufacturing market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Polyclonal Antibodies, Other Products
2) By Source: Mammalian, Microbial
3) Scale Of Operation: Preclinical, Clinical, Commercial
4) By End-User: Biopharmaceutical Companies, Research Laboratories, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Therapeutic Monoclonal Antibodies, Diagnostic Monoclonal Antibodies
2) By Polyclonal Antibodies: Research Polyclonal Antibodies, Therapeutic Polyclonal Antibodies
3) By Other Products: Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Fusion Proteins
Pre-Book The Antibody Contract Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Antibody Contract Manufacturing Market Size?
Leading corporations in the antibody contract manufacturing market are honing in on innovations like single-use technology to alleviate risks of cross-contamination and lower operational costs. Single-use technology (SUT) is applied to disposable components and systems in biopharmaceutical production procedures. For example, in September 2024, the US pharmaceutical firm Merck & Co. introduced the Mobius ADC Reactor, engineered to boost the production of antibody-drug conjugates. This unique single-use reactor increases production efficiency for antibody drug conjugates by 70% as compared to the traditional methods using stainless steel or glass. This single-use framework mitigates the risks of cross-contamination and running costs, enabling quicker turnaround times. Moreover, the use of cutting-edge film technology enhances bag durability and resistance to leaks, maintaining the purity of the highly potent active pharmaceutical components. This breakthrough aids biopharmaceutical companies in providing vital therapies in a safer, more efficient manner.
Who Are the Key Players in the Antibody Contract Manufacturing Market?
Major companies operating in the antibody contract manufacturing market include:
• AbbVie Inc.
• Thermo Fisher Scientific Inc.
• Boehringer Ingelheim Biopharmaceuticals GmbH
• Fujifilm Holdings Corporation
• Eurofins Scientific SE
• Lonza Group AG
• Labcorp Drug Development
• Catalent Inc.
• Charles River Laboratories International Inc.
• Merck KGaA
• Samsung Biologics Co. Ltd.
• Wuxi Biologics Cayman Inc
• Siegfried Holding AG
• Recipharm AB
• Emergent BioSolutions Inc.
• Aenova Group
• Cambrex Corporation
• Aldevron LLC
• Novasep Holding SAS
• Synthon
• KBI Biopharma Inc.
• Nitto Avecia Pharma Services Inc.
• Cytovance Biologics Inc.
• AGC Biologics S.p.A.
What are the Regional Insights into the Antibody Contract Manufacturing Market?
North America was the largest region in the antibody contract manufacturing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
